Why $IMMP soared in December case study

First time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy

Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 months from efti plus chemotherapy, compared to chemotherapy plus placebo.

Statistically significant OS benefit in efti group observed in pre-defined patient groups:

+7.1 months survival benefit (median of 21.9 vs. 14.8 months, nearly 50% longer) from efti with chemotherapy for patients under 65 years of age

+9.4 months survival benefit (median of 22.4 vs. 12.9 months, 74% longer) from efti with chemotherapy for patients with a low starting monocyte count

Statistically significant increase in CD8 T cells in patients treated with efti plus chemotherapy, correlated with prolonged OS, indicating pharmacodynamic activity and proof of concept of efti’s mode of action

Collection of OS data ongoing, with final data expected to be reported mid 2021

finance.yahoo.com/news/immutep-reports-statistically-significant-survival-221400435.html